Insider Transactions in Q1 2017 at Cvs Health Corp (CVS)
Insider Transaction List (Q1 2017)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
23,849
-13.46%
|
$1,860,222
$78.73 P/Share
|
|
Mar 21
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,637
+15.0%
|
$748,665
$45.07 P/Share
|
|
Mar 17
2017
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
6,029
-14.49%
|
$476,291
$79.6 P/Share
|
|
Mar 17
2017
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,029
+12.65%
|
$204,986
$34.96 P/Share
|
|
Mar 13
2017
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
14,104
-37.66%
|
$1,128,320
$80.4 P/Share
|
|
Mar 13
2017
|
Andrew Sussman EVP, Clinical Services |
BUY
Exercise of conversion of derivative security
|
Direct |
6,655
+22.59%
|
$299,475
$45.07 P/Share
|
|
Mar 10
2017
|
David M Denton EVP and CFO |
SELL
Open market or private sale
|
Direct |
95,618
-38.2%
|
$7,649,440
$80.68 P/Share
|
|
Mar 10
2017
|
David M Denton EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
95,618
+27.64%
|
$3,442,248
$36.23 P/Share
|
|
Feb 28
2017
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
32,722
-10.54%
|
$2,617,760
$80.58 P/Share
|
|
Feb 28
2017
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
68,255
+18.02%
|
$5,460,400
$80.58 P/Share
|
|
Feb 28
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,717
+13.82%
|
$1,737,360
$80.58 P/Share
|
|
Feb 28
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,304
-7.36%
|
$264,320
$80.58 P/Share
|
|
Feb 28
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,928
+18.11%
|
$794,240
$80.58 P/Share
|
|
Feb 28
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
15,512
+23.19%
|
$1,240,960
$80.58 P/Share
|
|
Feb 28
2017
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,512
+40.79%
|
$1,240,960
$80.58 P/Share
|
|
Feb 28
2017
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-10.59%
|
$152,960
$80.58 P/Share
|
|
Feb 28
2017
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
1,861
+15.5%
|
$148,880
$80.58 P/Share
|
|
Feb 28
2017
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
5,585
+23.62%
|
$446,800
$80.58 P/Share
|
|
Feb 28
2017
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
983
-1.36%
|
$78,640
$80.58 P/Share
|
|
Feb 28
2017
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,482
+6.38%
|
$198,560
$80.58 P/Share
|
|
Feb 28
2017
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,385
+7.6%
|
$110,800
$80.58 P/Share
|
|
Feb 28
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,132
-7.32%
|
$490,560
$80.58 P/Share
|
|
Feb 28
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,133
+16.14%
|
$1,290,640
$80.58 P/Share
|
|
Feb 28
2017
|
Robert O. Kraft EVP and President - Omnicare |
SELL
Payment of exercise price or tax liability
|
Direct |
1,256
-11.19%
|
$100,480
$80.58 P/Share
|
|
Feb 28
2017
|
Robert O. Kraft EVP and President - Omnicare |
BUY
Grant, award, or other acquisition
|
Direct |
3,809
+25.34%
|
$304,720
$80.58 P/Share
|
|
Feb 28
2017
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,506
-4.63%
|
$600,480
$80.58 P/Share
|
|
Feb 28
2017
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
18,615
+10.29%
|
$1,489,200
$80.58 P/Share
|
|
Feb 28
2017
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,705
-2.42%
|
$136,400
$80.58 P/Share
|
|
Feb 28
2017
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,205
+8.08%
|
$496,400
$80.58 P/Share
|
|
Feb 28
2017
|
Stephen J Gold EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,462
-11.04%
|
$276,960
$80.58 P/Share
|
|
Feb 28
2017
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
9,307
+22.89%
|
$744,560
$80.58 P/Share
|
|
Feb 27
2017
|
Robert O. Kraft EVP and President - Omnicare |
SELL
Payment of exercise price or tax liability
|
Direct |
422
-5.39%
|
$34,182
$81.41 P/Share
|
|
Feb 27
2017
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
189
-0.56%
|
$15,309
$81.41 P/Share
|
|
Feb 18
2017
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
355
-1.06%
|
$28,045
$79.69 P/Share
|
|
Feb 16
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
61,196
-68.03%
|
$4,895,680
$80.0 P/Share
|
|
Feb 16
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
61,196
+40.49%
|
$2,203,056
$36.23 P/Share
|
|
Feb 01
2017
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
76,494
-24.0%
|
$5,966,532
$78.32 P/Share
|
|
Feb 01
2017
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,494
+19.36%
|
$2,753,784
$36.23 P/Share
|